1. Pseudomonas Lung Infections in Cystic Fibrosis

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US.

3. Inhaled Antibiotics for Pseudomonas Infection in CF Are Standard of Care

4. Current Treatment Options

5. Inhaled Antibiotics in CF Clinical Questions

6. Role of Pseudomonas in Patients with CF

7. Continuum of Pseudomonas Infection

8. Early Pseudomonas Infection Control (EPIC) Study

9. Host Response to Pseudomonas Infection

10. Opportunities for Inhaled Antibiotics in CF

11. History of Inhaled Antibiotics in CF

12. In vitro Sputum Inhibition of P. aeruginosa With Tobramycin

13. Prolonged Exposure Study of Inhaled Tobramycin

14. Hypothesis

15. Crossover Study of Inhaled Tobramycin 28 and 56 d Treatments

16. Results of Inhaled Tobramycin Crossover Study

17. Inhaled Tobramycin in CF Phase 3 Trial Results

18. Guidelines for Inhaled Antibiotics in CF

19. Pseudomonas Eradication ELITE Study

20. Pseudomonas Eradication EPIC Study

21. Pseudomonas Eradication EPIC Study Results

22. What Is the Right Regimen? Rationale for Continuous Alternating Therapy

23. Options for Inhaled Antibiotic Therapy

24. CAT Study Design

25. CAT Study Shortcomings

26. Increased Use of Inhaled Antibiotics 1995-2005

27. Changes in Antibiotic Use 2009-2012

28. Can Inhaled Antibiotics Ever Be Discontinued?

29. When Resistance Is Present

30. Patient Adherence to Inhaled Antibiotics

31. Concluding Remarks

32. Abbreviations